CagriSema is a fixed-dose combination of two peptide-based drugs
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
This is technically true and profoundly misleading
Mechanisms investigated BPC-157 and TB-500 are structurally unrelated peptides studied through different pathways, which is the rationale for both the standalone reagents and the co-formulated blends: BPC-157 (gastric pentadecapeptide): a synthetic 15-amino-acid peptide derived from a protective protein in gastric juice, studied for cytoprotection, angiogenesis and epithelial healing in vitro and in animal models
Important things to consider for the rate of administration include: Watching the patients vital signs Changing the rate based on how the patient reacts Not giving it too fast to prevent bad reactions Emergency Protocols for Severe Deficiency For severe Vitamin B12 deficiency with neurological symptoms or severe anemia, emergency steps are needed
Why the 72-hour rule exists Numbers without context are just numbers